Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Adagene Inc. Sponsored ADR (ADAG) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Adagene Inc. Sponsored ADR is a member of our Medical group, which includes 975 different companies and currently sits at #7 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Adagene Inc. Sponsored ADR is currently sporting a Zacks Rank of #2 (Buy).The Zacks Consensus Estimate for ADAG's full-year earnings has moved 12.3% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.Based on the most recent data, ADAG has returned 10.6% so far this year. Meanwhile, the Medical sector has returned an average of -1.4% on a year-to-date basis. As we can see, Adagene Inc. Sponsored ADR is performing better than its sector in the calendar year.ANI Pharmaceuticals (ANIP) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 72.5%.Over the past three months, ANI Pharmaceuticals' consensus EPS estimate for the current year has increased 12.5%. The stock currently has a Zacks Rank #1 (Strong Buy).Looking more specifically, Adagene Inc. Sponsored ADR belongs to the Medical - Biomedical and Genetics industry, a group that includes 485 individual stocks and currently sits at #93 in the Zacks Industry Rank. Stocks in this group have gained about 5.2% so far this year, so ADAG is performing better this group in terms of year-to-date returns. ANI Pharmaceuticals is also part of the same industry.Going forward, investors interested in Medical stocks should continue to pay close attention to Adagene Inc. Sponsored ADR and ANI Pharmaceuticals as they could maintain their solid performance.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adagene Inc. Sponsored ADR (ADAG): Free Stock Analysis Report ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks